Dyadic International (DYAI) Interest & Investment Income (2023 - 2026)
Dyadic International (DYAI) posted Interest & Investment Income of $57191.0 for Q1 2026, down 31.12% sequentially from $83033.0 in Q4 2025, and down 35.35% YoY from $88458.0 in Q1 2025.
Dyadic International (DYAI) Interest & Investment Income (2023 - 2026) Analysis & Trends
Dyadic International has reported Interest & Investment Income for 4 years, with the latest figure at $57191.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 35.35% year-over-year to $57191.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252818.0 (down 44.8% YoY) and the FY2025 annual result came in at $284085.0, down 37.84% from the prior year.
- Interest & Investment Income fell to $57191.0 in Q1 2026 per DYAI's latest filing, from $83033.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $138471.0 in Q2 2024 and troughed at $49127.0 in Q2 2025.
- A 4-year average of $93458.0 and a median of $96899.0 in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income climbed 26.81% in 2024, then tumbled 64.52% in 2025.
- Over 4 years, Interest & Investment Income stood at $96899.0 in 2023, then increased by 7.07% to $103747.0 in 2024, then retreated by 19.97% to $83033.0 in 2025, then sank by 31.12% to $57191.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $57191.0, $83033.0, and $63467.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 57,191.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,191.00 |
| Dec 31, 2025 | 83,033.00 |
| Sep 30, 2025 | 63,467.00 |
| Jun 30, 2025 | 49,127.00 |
| Mar 31, 2025 | 88,458.00 |
| Dec 31, 2024 | 103,747.00 |
| Sep 30, 2024 | 127,331.00 |
| Jun 30, 2024 | 138,471.00 |
| Mar 31, 2024 | 87,443.00 |
| Dec 31, 2023 | 96,899.00 |
| Sep 30, 2023 | 105,862.00 |
| Jun 30, 2023 | 109,194.00 |
| Mar 31, 2023 | 104,731.00 |